News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Roche Says MabThera Gets Positive Phase III Data
October 26, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH, Oct 26 (Reuters) - Lymph cancer treatment MabThera has been shown to work as a maintenance therapy in patients with relapsed indolent non-Hodgkin's lymphoma, according to initial details from a Phase III study released by Roche on Wednesday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
Europe
Roche
MORE ON THIS TOPIC
Deals
BMS Commits up to $11B+ To Work With BioNTech on Solid Tumor Bispecific
June 2, 2025
·
2 min read
·
David Adam
Artificial intelligence
AstraZeneca Racks Up AI Partners, Seeking To Stop Cancer at All Stages
June 2, 2025
·
4 min read
·
Dan Samorodnitsky
Cancer
Arcus Kidney Cancer Drug Casdatifan Advances to Challenge Merck’s Welireg
June 2, 2025
·
2 min read
·
Nick Paul Taylor
Cancer
Bicara Responds to Rival Merus With Early Survival Data at ASCO25
June 2, 2025
·
2 min read
·
David Adam
